Vukmir, Rohrkaste lead bipartisan effort to lower drug prices
Bill would allow for pharmacists to switch brand-name biologics for biosimilars
MADISON, WIS. — Sen. Leah Vukmir, R–Brookfield, and Rep. Mike Rohrkaste, R–Neenah, unveiled a bipartisan bill Wednesday that would help patients get interchangeable versions of biologic prescription drugs and save them money.
This bill allows pharmacists to substitute biologic drugs approved by the Food and Drug Administration with their generic counterpart, called interchangeable biosimilars. Currently, pharmacists can only substitute generic forms of drugs produced chemically. This bill will now replicate that procedure for biologically created drugs and their biosimilars.
Patients are expected to get an estimated 20-percent savings by purchasing a biosimilar drug, as opposed to the brand-name version.
“Everyone knows that buying generic versions of brand-name prescription drugs can produce significant savings for families and seniors,” said Vukmir, a nurse and chairman of the Senate Health and Human Services Committee. “Now that science allows us to create biosimilar drugs, we need to work to make sure Wisconsinites can get these savings at the pharmacist whenever possible.”
“This bill will help improve healthcare outcomes and use healthcare dollars more efficiently,” Rohrkaste added.
Biologic drugs have helped improve the quality of life for people with arthritis, cancer, leukemia, MS, diabetes, and epilepsy. Thirty-five states have passed similar laws to help consumers get access to interchangeable biosimilar drugs.
Recent Press Releases by State Sen. Leah Vukmir
"Tammy Baldwin and her extreme left allies are using every smear tactic and despicable trick in an attempt to silence us, beat us and obstruct reforms that will help the American middle class."
“Senator Baldwin let us down by sitting on the Inspector General’s report that detailed the problems at the Tomah VA that endangered veterans,” said Leah Vukmir campaign manager Jess Ward.
Baldwin also denied a plea from VA whistleblower Ryan Honl to make the report public that would’ve spurred action.